Sertraline Tablets — Class II drug recall D-0205-2024
Ongoing recall by Legacy Pharmaceutical Packaging LLC, reported 2024-01-03, distributed in AR, CA. CGMP Deviations: Inadequate line clearance which may result in a potential comingling of product.
| Recall number | D-0205-2024 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Legacy Pharmaceutical Packaging LLC, Earth City, MO, United States |
| Recall initiated | 2023-12-11 |
| Classified | 2023-12-26 |
| Reported by FDA | 2024-01-03 |
| Distributed | AR, CA |
| Quantity | 161,664 bottles |
| Reason classes | cgmp |
| NDC | 68645-0521, 68645-0521-54, 68645-0522, 68645-0522-54, 68645-0523, 68645-0523-54 |
| Lot numbers | 222033 |
| Expiration dates | 2024-08-31 |
Product
Sertraline Tablets, USP 100 mg, 30 tablets per bottle, Distributed by: Wal-Mart, Bentonville, AR 72716, Manufactured for: Cipla USA, Inc., Warren, NJ 07059, Packaged by: Legacy Pharmaceutical Packaging LLC., Earth City, MO 63045, NDC# 68645-523-54
Reason for recall
CGMP Deviations: Inadequate line clearance which may result in a potential comingling of product.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0205-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.